- Home
- BAP vs GMAB Comparison
BAP vs GMAB Comparison
Compare BAP & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAP
- GMAB
- Stock Information
- Founded
- BAP 1889
- GMAB 1999
- Country
- BAP Peru
- GMAB Denmark
- Employees
- BAP N/A
- GMAB N/A
- Industry
- BAP Major Banks
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- BAP Finance
- GMAB Health Care
- Exchange
- BAP Nasdaq
- GMAB Nasdaq
- Market Cap
- BAP 21.1B
- GMAB 17.4B
- IPO Year
- BAP 1995
- GMAB N/A
- Fundamental
- Price
- BAP $256.59
- GMAB $30.18
- Analyst Decision
- BAP Buy
- GMAB Strong Buy
- Analyst Count
- BAP 6
- GMAB 6
- Target Price
- BAP $245.00
- GMAB $40.40
- AVG Volume (30 Days)
- BAP 224.7K
- GMAB 2.4M
- Earning Date
- BAP 11-13-2025
- GMAB 11-06-2025
- Dividend Yield
- BAP 4.37%
- GMAB N/A
- EPS Growth
- BAP 26.90
- GMAB 132.41
- EPS
- BAP 22.19
- GMAB 25.10
- Revenue
- BAP $5,576,317,301.00
- GMAB $3,845,670,022.00
- Revenue This Year
- BAP $24.87
- GMAB $24.92
- Revenue Next Year
- BAP $7.51
- GMAB $15.97
- P/E Ratio
- BAP $11.36
- GMAB $1.20
- Revenue Growth
- BAP 20.05
- GMAB 29.57
- 52 Week Low
- BAP $165.51
- GMAB $17.24
- 52 Week High
- BAP $280.88
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- BAP 47.37
- GMAB 56.27
- Support Level
- BAP $255.00
- GMAB $28.08
- Resistance Level
- BAP $262.73
- GMAB $30.78
- Average True Range (ATR)
- BAP 7.04
- GMAB 0.68
- MACD
- BAP -0.26
- GMAB 0.10
- Stochastic Oscillator
- BAP 76.49
- GMAB 84.07
About BAP Credicorp Ltd.
Credicorp Ltd is a Peruvian financial services company. It operates in four business lines, including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital. Geographically, the company operates in Peru, Colombia, Bolivia, Chile, Panama, the USA, and Mexico; the majority of its revenue is generated from Peru.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.